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Abstract: We used the Manitoba Health database to examine the relationship between use of 
inhaled respiratory drugs in people with chronic obstructive respiratory diseases and cardiovas-
cular hospitalizations from 1996 through 2000. The drugs examined were beta agonists [BA], 
ipratropium bromide IB, and inhaled steroids (ICS). End points were ﬁ  rst hospitalizations for 
supraventricular tachycardia, myocardial infarction, heart failure or stroke. A nested case control 
analysis was employed comparing people with and without cardiovascular events. Cases and 
controls were matched for gender and age, and conditional logistic regression was used in mul-
tivariate analysis considering other respiratory drugs, respiratory diagnosis and visit frequency, 
non-respiratory, non-cardiac comorbidities, and receipt of drugs for cardiovascular disease.
In univariate analyses, BA, IB and ICS were all associated with hospitalizations for cardio-
vascular disease, but in multivariate analyses ICS did not increase risk while both BA and IB 
did. There were interactions between respiratory and cardiac drugs receipt in that bronchodila-
tor associated risks were higher in people not taking cardiac drugs; this was especially true for 
stroke. There were strong interactions with speciﬁ  c cardiac drugs; for example, both BA and IB 
substantially increased the risk of supraventricular tachycardia in patients not anti-arryhthmic 
agents, but not in the presence of such agents.
We conclude that bronchodilator therapy for chronic obstructive diseases is associated 
with increased cardiovascular risk, especially in patients without previous cardiovascular 
diagnoses, and that this is unlikely due to the severity of the respiratory disease, since risk was 
not increased with ICS.
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Bronchodilators are widely used and effective drugs for the treatment of obstructive 
lung diseases. However, concerns have been raised about possible associations of 
these drugs with cardiovascular morbidity and mortality. Most reports have implicated 
inhaled beta agonists (BA), especially in patients with preexisting cardiac disease 
(Coughlin et al 1995; Au et al 2002, 2003, 2004; Salpeter et al 2004), but other studies 
have not found an association between these agents and cardiovascular outcomes 
(Suissa et al 1994, 1996, 2003). The other widely used bronchodilator, the anticholiner-
gic ipratropium bromide (IB), has been less extensively studied in this regard. A large 
clinical trial involving IB in patients with mild COPD found a trend toward increased 
cardiovascular mortality and supraventricular tachycardias requiring hospitalization 
among participants assigned to IB as opposed to placebo (Anthonisen et al 2002). 
An association between IB and mortality had been noted previously in asthmatics 
(Guite et al 1999), but may have been confounded, since IB is more commonly used 
in COPD, and the two diseases are often confused. A retrospective cohort study also 
found IB use associated with increased mortality in both COPD and asthma (Ringbaek 
and Viskum 2003), but a large database study did not (Sin and Tu 2000).International Journal of COPD 2008:3(1) 164
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It is well known that COPD patients have an increased 
risk of death from cardiovascular disease related to their 
smoking history and reduced lung function (Sin and Mann 
2003; Sin et al 2005). There is also substantial prevalence of 
asymptomatic supraventricular and ventricular arrhythmias 
in people with severe COPD (Hudson et al 1973; Kleiger 
and Senior 1974). It is therefore conceivable that inhaled 
beta agonists or anti-cholinergics such as IB could cause 
arrhythmias and cardiovascular events in COPD patients. 
We have explored this possibility.
Methods
Data source
The Province of Manitoba provides universal health care 
insurance for all its residents (approximately 1.1 million). For 
research purposes, the Manitoba Population Health Research 
Repository integrates anonymous records of all inpatient and 
outpatient physician contacts, vital statistics (date and cause 
of death) and prescription records. In addition, it is linked via 
an anonymous identiﬁ  er to the Population Registry, which 
indicates the duration of health insurance coverage for each 
permanent Manitoba resident, coverage ending with leaving 
the province or with death. Physicians are remunerated on 
the basis of claims for payment describing services provided 
and the diagnosis for which services were rendered. The Drug 
Programs Information Network (DPIN) database is created 
by provincial retail pharmacies entering prescriptions in real 
time in order to facilitate screening for inappropriate use, such 
as drug interactions, and co-payment for medication. The 
pharmaceutical database contains the individual anonymous 
identiﬁ  er, as well as the information about the drug dispensed: 
the anatomical therapeutic chemical (ATC) code, drug identiﬁ  -
cation number (DIN), date, quantity dispensed, and the number 
of days covered by the medication supplied (WHO 1995).
Subjects
We identiﬁ  ed all people over 35 years of age who, between 
January 1, 1996 and December 31, 2000, had a physician 
contact for bronchitis (ICD-9 code 490) asthma (ICD-9 code 
493) or COPD (ICD-9 codes 490, 491, 492, and 496) (WHO 
1978). Subjects were permanent residents of the province 
on January 1, 1996 or at ﬁ  rst physician contact after that 
date and were observed until leaving the province, death or 
December 31, 2000.
Variables
The outcome was the ﬁ  rst hospitalization between January 1, 
1996, and December 31, 2000, for selected cardiovascular 
events: supra-ventricular tachycardia (SVT) (ICD-9 427.0, 
427.31, 427.32, 427.61), myocardial infarction (MI) (ICD-9 
410), heart failure (HF) (ICD-9 428), and stroke (ICD-9 
430-438).
Patients were classiﬁ  ed according to sex, age, and respi-
ratory diagnostic group: asthma, COPD, both asthma and 
COPD, and bronchitis. Patients in the ﬁ  rst three groups could 
also have visits for bronchitis. Three groups of respiratory 
drugs were examined: inhaled beta agonists (BA), inhaled 
anti-cholinergics (IB), and inhaled corticosteroids (ICS). We 
recorded physician visits for respiratory diagnoses and for 
non-cardiac co-morbidities, and to assess cardiac co-morbidi-
ties we noted recipients of cardiac drugs. Non-cardiac co-
morbidities were derived from physician claims for paralysis 
(ICD-9 342–344), diabetes (ICD-9 250), renal failure (ICD-9 
403, 404, 582, 583, 585, 586, 588), liver disease (ICD-9 070, 
456, 571, 572), peptic ulcer (ICD-9 531–534), malignancy 
(ICD-9 200–203, 238, 273), collagen vascular disease (ICD-9 
701, 710, 714, 720, 725) and dementia (ICD-9 290, 797). In 
assessing cardiac co-morbidities, cardiac medications were 
classiﬁ  ed into 8 categories: anti-arrhythmics (excluding 
beta-blockers), nitrates, furosemide, beta-blockers, calcium 
channel blockers, angiotensin converting enzyme inhibitors 
(ACEI), other anti-hypertensives, and cholesterol lowering 
agents. To assess co-morbidities, anti-arrhythmics were 
excluded from the analyses of SVT.
Design
We performed a nested case-control analyses with the ﬁ  rst 
hospitalization for a speciﬁ  ed cardiovascular event deﬁ  ning 
the case. The date of hospitalization of the case deﬁ  ned the 
index date. Each case was matched according to sex, age and 
duration of insurance coverage with up to ten control subjects 
that did not have that event prior to the index date. The con-
trol subjects were selected randomly if more than ten were 
available for a case. Respiratory drug exposure was analyzed 
according to receipt of one of the three types of drugs 60 days 
or 365 days prior to the event; it should be noted that those 
exposed within 365 days included those exposed within 60 
days. Cardiac drug exposure was deﬁ  ned by receiving cardiac 
drugs within 365 days prior to the index date.
Analysis
Conditional logistic regression was used. Odds ratios (OR) 
and conﬁ  dence intervals (95% CI) were calculated and results 
were considered statistically signiﬁ  cant if p < 0.05. Analyses 
were conducted using SAS software, version 8.2 (SAS Insti-
tute, Inc., Cary, North Carolina). Univariate models assessed International Journal of COPD 2008:3(1) 165
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the association of each drug group and exposure with each 
outcome. In multivariate models, we successively added 
other respiratory drugs, respiratory diagnostic group, number 
of physician visits for respiratory diagnoses, non-cardiac 
co-morbidities, and cardiac drugs.
We also tested for interactions between cardiac drugs, 
taken as a whole, and respiratory drugs for each of the out-
comes and looked for interactions with speciﬁ  c cardiac medi-
cations as follows: SVT (antiarrhythmics), MI (all except 
antiarrhythmics), HF (all except anticholesterol agents) and 
stroke (all cardiac drugs).
The Ethics Board of the University of Manitoba and the 
Health Information Privacy Committee of Manitoba Health 
approved the study.
Results
A total of 222,272 of Manitoba residents with a respiratory 
diagnosis were enumerated during 5 years ending on Decem-
ber 31, 2000. Characteristics of cases and controls are shown 
in Table 1 by cardio-vascular diagnosis at the time of the 
ﬁ  rst hospitalization. The proportion of males was the highest 
(61.7%) among those hospitalized for myocardial infarction 
while those hospitalized for HF were the oldest (76.0 years). 
A relatively small proportion of cases received respiratory 
drugs during the year prior to the hospitalization, the highest 
being people with HF: about one third received BA. Use of 
BA and IB was more common in cases than controls. Also, 
ICS use was more common in cases, except for those with 
stroke. With respect to respiratory morbidity, cases and con-
trols were well balanced for SVT, MI and stroke. For HF, a 
greater proportion had a history of COPD. As expected, use 
of cardiac drugs was substantially greater among cases than 
among controls. Non-cardiac co-morbidities were also more 
common in cases than in controls.
Tables 2–5 show univariate and multivariate associations 
between respiratory drugs and cardiovascular hospitaliza-
tions. The likelihood of a hospitalization for SVT, MI, and 
HF was signiﬁ  cantly increased for those to whom BA, IB, 
or ICS were dispensed within 60 days or one year prior to 
the hospitalization. The association was weaker for those 
hospitalized because of a stroke. When all three categories of 
respiratory drugs were ﬁ  t into the multiple logistic regression 
model simultaneously, the ORs diminished for each respiratory 
drug and all outcomes. However, they remained signiﬁ  cantly 
increased for BA and IB. The ORs associated with ICS became 
not signiﬁ  cant or even signiﬁ  cantly protective (ICS within 60 
days for SVT, HF, and stroke, and 365 days for HF and stroke). 
Addition of respiratory diagnoses and visit frequency to the 
model did not further affect the ORs. Similarly, the addition 
of non-respiratory, non-cardio-vascular co-morbidity to the 
model did not have an effect on the ORs.
There were signiﬁ  cant interactions between cardiac drugs 
(as a group) and the bronchodilators, also shown in Tables 
2–5. The use of cardiac drugs decreased the likelihood of 
hospitalization associated with IB and BA (for SVT and 
stroke) and BA (for stroke). IB and BA increased the risk of 
stroke in people not taking cardiac drugs, but not when they 
were taking them.
Table 6 shows the effects of speciﬁ  c cardiac drugs on 
the risk of hospitalization associated with bronchodilators. 
Anti-arrhythmics were not included in the initial tests for 
interaction with SVT because their use closely coincided 
with the diagnosis. They abolished the increased risk for SVT 
with both bronchodilators at both time points. Furosemide 
reduced but did not eliminate the increased risk of heart 
failure with both bronchodilators at both time points, as did 
angiotensin inhibitors in the case of beta agonists. Patients not 
on angiotensin inhibitors had an increased risk of stroke with 
IB, as was the case with patients not on anti-hypertensives 
who used beta agonists.
Discussion
Our ﬁ  nding that BA use was associated with cardiovascu-
lar morbidity was consistent with others in the literature 
(Coughlin et al 1995; Au et al 2002, 2003, 2004; Salpeter et al 
2004), and with the pharmacology of these drugs (Robin and 
McCauley 1992; Iskander et al 2004; Kallergis et al 2005). 
Suissa et al have failed to ﬁ  nd such associations but one of 
their studies (Suissa et al 1996) noted that nebulized or orally 
administered BA were associated with cardiac deaths, and 
another (Suissa et al 1994) was conﬁ  ned to asthmatics, who 
are less likely to have cardiovascular events than people 
with COPD.
We also found that IB use was associated with cardiovas-
cular events to more or less the same extent as BA. This was 
not entirely unprecedented; a large clinical trial comparing IB 
with placebo in mild COPD noted increased cardiovascular 
morbidity and mortality of borderline signiﬁ  cance in the 
group assigned IB, and a particularly suggestive increase 
in the incidence of SVT (Anthonisen et al 2002). This was 
consistent with the vagolytic nature of the drug if it was 
absorbed (Coleman et al 1975), and arrhythmias appear to be 
the most credible mechanism for IB to cause cardiovascular 
events. Other studies associating IB with excess mortality 
(Guite et al 1999; Rigbaek and Viskum 2003) suffered from 
potential confounders in that IB use was associated with International Journal of COPD 2008:3(1) 166
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disease severity and/or the diagnosis of COPD as opposed to 
asthma. Using a very large database, Sin and Tu (2000) did 
not ﬁ  nd and association between IB and mortality in COPD 
patients after adjustment for potential confounders.
The strength of any conclusions in regard to our data 
depends on the validity of our approach. Our database is 
inclusive and detailed. It included all residents of Manitoba: 
approximately 1.1 million people. We were able to enumerate 
Table 1 Characteristics of cases (at ﬁ  rst hospitalization) and controls
   SVT  Controls  MI  Controls  HF  Controls  Stroke  Controls
    cases   cases    cases   cases 
Number of subjects  2054  20501  3855  38490  5407  53929  4961  49487
Gender  Males  48.2   61.7    49.8   49.8 
Age  mean  71.2   69.1    76.0   73.4 
  25th , 75th percentile  64, 80    61, 79    70, 84    67, 82 
Respiratory Co-morbidity
 Asthma  10.1  10.9  9.6  11.0  7.1  9.1  8.0  10.0
  COPD  27.1 26.3  29.5  25.6  41.7 28.9  31.5  27.9
  Asthma and COPD  10.5  9.1  10.8  9.5  13.3  10.1  9.4  10.0
  Bronchitis  52.3 53.7  50.1  53.9  37.9 52.1  51.1  52.2
Any Non-cardiac Co-morbidity  39.5  34.0   44.4  32.9  51.7  35.8  46.2  34.9
Drug dispensed within
  IB    60 Days  7.8  4.8  6.6  4.7  14.9  5.4  5.6  5.0
        1  Year  11.2 7.6  10.3  7.5  20.4 8.4  10.1  7.9
  BA  60 Days  13.2  9.3  13.1  9.4  24.4  10.1  10.5  9.8
        1 Year  22.4  17.2  21.1  16.8  34.3  17.6  19.3  17.4
  ICS  60 Days  7.2  6.4  7.9  6.2  12.0  6.9  6.1  6.7
        1 Year  13.5  11.3  14.0  11.6  18.7  12.0  11.6  11.7
Cardiac Drugs
  Antiarrhythmics  36.8 9.2  11.8  7.9  34.6 9.8  16.8  9.6
  Nitrates  31.0 16.1  30.1  13.7  40.7 16.6  25.0  16.4
  Antihypertensives  37.5 27.6  32.4    25.7  42.0 28.8  37.8  28.1
  Furosemide  33.9 17.3  23.8    14.5  65.0 18.8  27.8  18.2
  Betablockers  29.4 14.1  20.1    12.8  20.7 13.8  20.4  13.8
  Calcium Channel Blockers  16.5  7.6  12.4   6.6  15.2  7.7  11.3  7.4
  ACEI  37.1 21.9  30.2  20.5  52.4 21.6  34.9  21.9
  Anticholesterol  13.0 10.5  15.1  10.2  12.1 9.2  13.8  9.4
  Any  81.2 55.3  67.4  51.6  88.9 58.6  73.2  56.7
Table 2 Odds ratios for the ﬁ  rst hospitalization due to SVT
     Univariate    Multivariate
      All Plus Plus Plus  Interaction  No  cardiac  Cardiac
     respiratory  respiratory  other  cardiac  with  cardiac  drugs  drugs
      drugs  comorbidity comorbidity drugs  drugs
            p-value
60  Days  IB  1.68  1.48  1.49 1.49 1.38  0.011  2.38  1.24
    1.41, 2.00  1.19, 1.84  1.20, 1.86  1.20, 1.85  1.10, 1.72    1.51, 3.74  0.99, 1.55
  BA  1.48  1.40  1.40 1.37 1.31  0.05  
    1.29, 1.70  1.17, 1.67  1.16, 1.69  1.14, 1.64  1.09, 1.57     
  CS  1.13  0.79  0.79 0.80 0.79  0.05  
    0.95, 1.35  0.64, 0.98  0.64, 0.98  0.65, 0.99  0.64, 0.99     
              
1  year  IB  1.53  1.33  1.36 1.36 1.27  0.046  1.80  1.17
    1.32, 1.77  1.12, 1.59  1.13, 1.63  1.13, 1.63  1.06, 1.53    1.22, 2.65  0.97, 1.41
  BA  1.40  1.32  1.35 1.32 1.25  0.05  
    1.25, 1.56  1.14, 1.53  1.16, 1.57  1.14, 1.54  1.07, 1.46     
  CS  1.23  0.93  0.96 0.96 0.93  0.05  
    1.07, 1.40  0.78, 1.09  0.80, 1.14  0.80, 1.14  0.78, 1.11     International Journal of COPD 2008:3(1) 167
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Table 3 Odds ratios for ﬁ  rst hospitalization due to myocardial infarction
     Univariate    Multivariate   
     All  Plus  Plus  Plus  Interaction
     respiratory  respiratory  other  cardiac  with  cardiac
     drugs  comorbidity  comorbidity  drugs  drugs
            p-value
60  Days  IB  1.42 1.13 1.05  1.04  1.00  0.05
    1.24, 1.63  0.96, 1.33  0.89, 1.23  0.88, 1.23  0.85, 1.18 
 BA  1.46 1.39 1.35  1.33  1.31  0.05
    1.32, 1.61  1.22, 1.59  1.18, 1.55  1.16, 1.53  1.15, 1.51 
 CS  1.30 1.01 1.01  1.04  0.99  0.05
    1.15, 1.48  0.87, 1.17  0.87, 1.18  0.89, 1.22  0.85, 1.16  
           
1  year  IB  1.40 1.22 1.13  1.11  1.07  0.05
    1.25, 1.57  1.07, 1.39  0.98, 1.29  0.97, 1.28  0.93, 1.23 
 BA  1.33 1.24 1.22  1.18  1.15  0.05
    1.22, 1.44  1.11, 1.39  1.08, 1.36  1.05, 1.32  1.02, 1.29 
 CS  1.24 1.00 1.02  1.04  1.01  0.05
    1.13, 1.37  0.89, 1.13  0.89, 1.16  0.91, 1.18  0.89, 1.15 
Table 4 Odds ratios for ﬁ  rst hospitalization due to heart failure
     Univariate    Multivariate   
      All Plus Plus Plus  Interaction 
     respiratory  respiratory  other cardiac  with  cardiac 
      drugs  comorbidity comorbidity drugs  drugs
            p-value
           
60  Days  IB  3.07  1.80  1.59 1.59 1.47  >0.05
    2.82, 3.34  1.62, 2.00  1.43, 1.77  1.62, 1.78  1.31, 1.64 
  BA  2.88  2.45  2.25 2.21 1.99  >0.05
    2.69, 3.08  2.23, 2.68  2.04, 2.47  2.00, 2.43  1.81, 2.20 
  CS  1.84  0.82  0.83 0.87 0.85  >0.05
    1.69, 2.02  0.73, 0.91  0.74, 0.92  0.78, 0.97  0.76, 0.95 
           
1  year  IB  2.80  1.90  1.69 1.68 1.55  >0.05
    2.60, 3.01  1.73, 2.08  1.54, 1.86  1.53, 1.85  1.41, 1.71 
  BA  2.45  2.15  2.03 1.96 1.74  >0.05
    2.31, 2.61  1.98, 2.33  1.86, 2.21  1.79, 2.13  1.60, 1.91 
  CS  1.69  0.78  0.82 0.84 0.82  >0.05
    1.57, 1.82  0.71, 0.86  0.74, 0.90  0.76, 0.93  0.75, 0.91
claims for hospitalization, physician visits and all respiratory 
medications received by each subject with bronchitis, COPD 
or asthma. We attempted to control for disease severity 
and for cardiac and non-cardiac co-morbidities. As with all 
database studies, this had several important weaknesses. 
We cannot be certain of the accuracy of the diagnoses we 
were concerned with, though the accuracy of diagnosis of 
ischemic heart disease and COPD has been reported from a 
similar database (Curkendall et al 2006); agreement between 
databases and survey results is at best “moderate” in chronic 
diseases such as asthma (Huzel et al 2002). In the absence 
of laboratory data, we used proxies such as other drugs and 
physician visits to assess severity. We equated drug use with 
drug dispensing, and did not know whether patients actually 
used the medications that they received, though drug effects 
were most prominent in the 60 days after drug prescriptions, 
when it was reasonable to assume that the drugs were actually 
used. Although we adjusted for co-morbidities, such adjust-
ments are approximations. We limited our analyses to ﬁ  rst 
hospitalization for a cardiovascular diagnosis, thereby avoid-
ing the weakness that pharmacy-derived drug databases do 
not enumerate drugs administered to hospitalized patients.
An alternative explanation for our results would be that 
bronchodilator use reﬂ  ected severity of obstructive lung 
disease in a way that was not captured by our other measure-
ments such as physician visits. There is excellent evidence International Journal of COPD 2008:3(1) 168
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Table 5 Odds ratios for ﬁ  rst hospitalization due to stroke
     Univariate    Multivariate   
     All  Plus  Plus  Plus  Interaction  No  cardiac  Cardiac 
     respiratory  respiratory  other cardiac  with  cardiac  drugs  drugs
     drugs  comorbidity  comorbidity  drugs  drugs
             p-value
               
60 Days  IB  1.18  1.20  1.09  1.10  1.04  0.001 1.46  0.96
    1.04, 1.33  1.03, 1.40  0.93, 1.27  0.94, 1.28  0.90, 1.22    1.05, 2.03  0.81, 1.14
 BA  1.08  1.11  1.05  1.05  1.01  0.001 1.32  0.94
    0.98, 1.19  0.98, 1.26  0.92, 1.19  0.92, 1.19  0.90, 1.15    1.05, 1.67  0.81, 1.08
 CS  0.90  0.79  0.78  0.80  0.78  0.05  
    0.80, 1.02  0.68, 0.91  0.67, 0.90  0.69, 0.92  0.67, 0.90     
               
1 year  IB  1.30  1.32  1.20  1.18  1.13  0.001 1.44  1.06
    1.18, 1.44  1.17, 1.48  1.07, 1.36  1.05, 1.34  1.00, 1.27    1.11, 1.87  0.93, 1.21
 BA  1.13  1.12  1.08  1.06  1.01  0.001 1.31  0.95
    1.05, 1.22  1.01, 1.24  0.97, 1.19  0.96, 1.17  0.92, 1.12    1.09, 1.57  0.85, 1.07
 CS  0.99  0.84  0.84  0.85  0.83  0.05  
    0.90, 1.08  0.75, 0.93  0.75, 0.94  0.76, 0.96  0.74, 0.94     
Table 6 Signiﬁ  cant interactions between respiratory drugs and cardiac drug classes associated with causes of hospitalization*
Respiratory drugs  Dispensed within  60 Days      365 Days   
Cardiac drugs    Off  On  p value  Off  On  p value
SVT IB  and  Antiarrhythmics  1.76  0.72  0.0001 1.53  0.72  0.0001
    1.36, 2.27  0.52, 0.99    1.24, 1.89  0.55, 0.94 
 BA  and  Antiarrhythmics  1.32  0.77  0.0004  1.31  0.8  0.0001
    1.09, 1.61  0.60, 1.00    1.12, 1.52  0.65, 0.99 
Myocardial infarction  BA and Nitrates        1.26  1.00  0.012
          1.13, 1.41  0.86, 1.17 
Heart failure  IB and Furosemide  1.75  1.18  0.0002  1.73  1.26  0.0005
    1.45, 2.10  1.04, 1.34    1.48, 2.03  1.13, 1.40 
  BA and Furosemide  2.22  1.45  0.0001 1.68  1.28  0.0002
    1.94, 2.54  1.30, 1.61    1.50, 1.89  1.17, 1.41 
 BA  and  ACEI  2.17  1.87  0.0417
    1.94, 2.43  1.66, 2.10
Stroke IB  and  ACEI  1.26  0.88  0.006  1.33  1.01  0.01
    1.05, 1.50  0.70, 1.09    1.15, 1.54  0.86, 1.20 
  BA  and  Antihypertensives  1.06 0.84 0.018  1.06  0.89 0.03
    0.93, 1.21  0.71, 0.99    0.95, 1.17  0.78, 1.01 
*Shown are odds ratios relating bronchodilators (IB or BA) to hospitalization for cardiovascular disease when patients were using (On) and not using (Off) groups of 
cardiac drugs.
that cardiovascular events are common in COPD and that 
this relates to the degree of airways obstruction (Sin and Man 
2003; Sin et al 2005). Arrhythmias have been documented 
as common in patients with severe COPD (Hudson et al 
1973; Kleiger and Senior 1974), though it was likely these 
assessments were made in patients who were being treated 
with beta agonists. We cannot deﬁ  nitively refute the argu-
ment that bronchodilators were simply a marker of disease 
severity and this accounted for their association with cardio-
vascular disease, but we think it unlikely for two reasons. 
First, use of ICS was not associated with these outcomes. 
ICS are recommended only in severe COPD as opposed to 
bronchodilators, recommended in all symptomatic cases. 
Cardiovascular risk was associated with bronchodilators, 
and not ICS, also markers of COPD severity. Further, the 
association of bronchodilators with cardiovascular outcomes 
was present in patients whose only diagnosis was bronchitis, 
a group with relatively few markers of disease severity such 
as physician visits and respiratory hospitalizations.
People who had cardiovascular events were more 
likely to be taking cardiac drugs than those who did not 
(Tables 1 and 2), as was expected. Of some surprise was International Journal of COPD 2008:3(1) 169
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the ﬁ  nding that there were signiﬁ  cant interactive effects 
between bronchodilators and cardiac drugs taken as a whole 
(Table 3); in all cases cardiac drugs decreased the likelihood 
of cardiovascular events associated with bronchodilators, 
especially IB. The example of stroke was especially striking; 
on the whole bronchodilators did not increase stroke risk after 
adjustment for confounders, but risk was apparently depen-
dent upon precognition of cardiovascular disease, since it was 
increased in those on bronchodilators who were not taking 
cardiac drugs. Speciﬁ  c drug interactions supported this inter-
pretation (Table 6); in each case the receipt of speciﬁ  c cardiac 
drugs decreased the likelihood of hospitalizations associated 
with bronchodilator. A particularly notable example of this 
kind of drug interaction was the fact that bronchodilators 
did not increase the risk of arrhythmia in the presence of 
anti-arrhythmic agents. Bronchodilators apparently impose 
a larger relative risk in people with unrecognized cardiovas-
cular disease than in people with known disorders.
As noted above, ICS were not associated with cardiovas-
cular events. Indeed, they appeared to be protective, an effect 
that was occasionally signiﬁ  cant. We have previously shown 
in a similar cohort that ICS were associated with reduced 
cardiovascular mortality as compared to patients taking 
bronchodilators in the absence of ICS (Macie et al 2006). 
It is possible that the beneﬁ  cial effect of ICS is dependent 
upon reduction of cardiovascular events associated with 
bronchodilator therapy, since ICS are seldom used in the 
absence of bronchodilators.
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